Medical network - on April 12, April 11, is the world Parkinson's disease. Formerly known as parkinsonism, Parkinson's disease is a common chronic disease of the central nervous system. According to the world Parkinson's disease association statistics, the world more than 500 Parkinson's disease, Parkinson's disease in the elderly over 60 rate has reached 1%, more than 70 - year - old prevalence was 3% ~ 5%. 

 

China is now more than 200 Parkinson's disease, with rapid aging society coming, 60 years old or older has more than 220 million people in China, each year almost 100000 new cases of Parkinson's disease, thus constituted a specific demand of the market space. 

 

Medicine companies chasing hot spots 

 

Parkinson's disease is the current domestic and international pharmaceutical market basic standards, drug use has become a hot domestic drug firms to pursue, in the perfect structure of drugs at the same time, the objective will lead to the development of Parkinson's disease drug market. According to m Intranet "China city public hospital chemical medicine terminal monitoring analysis system" (HDM) data, forecast in 2016 key cities for the domestic public hospital the Parkinson's drug totaling 390 million yuan, a year-on-year growth of 12.76% a year. 

 

 

 

1, pramipexole, "leading" growth 

 

Pramipexole (Pramipexole) as the total synthesis of ergot dopamine agonists, highly selective stimulation of dopamine receptor, thus improve the symptoms of patients. Pramipexole by German boehringer ingelheim corporation development, the American FDA approved in July 1997, commodity called "Sifrol". 

 

Pramipexole after entering the patient, can be highly selective role in the production of dopamine receptor 2 subtypes, to dopamine nerves have better protection, can delay the disease development, is the best choice for treatment of early Parkinson's disease, also can be used in combination treatment with advanced Parkinson's disease, many countries in Europe and the United States has become a first-line drug treatment of Parkinson's disease. 

 

On September 12, 2003, boehringer ingelheim pramipexole in China to obtain authorization of the administrative protection, then allowed to list in China, goods, Florida. In August 2014, the CFDA approved pramipexole zyban, has now become a Parkinson's drug resistance in recent years, "leader" of the market. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital drug pramipexole total amount of 133 million yuan, year-on-year growth of 18.93% a year, in the key cities for the largest public hospital drug use in Parkinson's disease. 

 

 

 

2, levodopa: rule of imported drugs market 

 

Parkinson's disease, in 65 years of age or older and commonly associated with cognitive impairment was found and treatment of this phase is much preferred compound levodopa drug. HDM system data, predicted in 2016 key cities for the domestic public hospital levodopa/benzyl silk hydrazine drugs amount is 62.04 million yuan, a year-on-year growth of 6.62% a year. 

 

 

 

Levodopa class is based drugs in the treatment of Parkinson's disease, the main varieties are levodopa and dopamine silk hydrazine, carbidopa and levodopa/carbidopa four drugs, such as the four drugs are completely to realize localization production. Levodopa is an amino acid precursor of dopamine drugs, although on the market for many years, now is still a most important drug in the treatment of Parkinson's disease. 

 

CFDA has approved eight domestic enterprises producing levodopa apis, 28 companies production preparation, main formulations are tablets, capsules and injection. Levodopa and peripheral dopa decarboxylase inhibitor carbidopa hydrazine share or benzyl silk, with peripheral dopa decarboxylase inhibitor share, prevent levodopa and outer flow into dopamine, can reduce the peripheral adverse reaction, increase the amount of entering the brain, use, and make clinical response more smoothly. Domestic sinistral more evidently than dopamine compound preparation by nantong essence pharmaceutical group exclusive listing, seraiah commodity called beauty. 

 

Levodopa benzyl silk hydrazine in domestic five companies hold production approval, but roche sustained-release capsules and tablets "dopamine" is still up 99% share in the market, Shanghai preplex foda pharmaceutical pharmaceutical co., Shanghai levodopa hydrazine benzyl silk compound capsule preparation share is smaller. 

 

Levodopa class started drug curative effect is very good, but the long-term medication are prone to "long-term levodopa syndrome". On the other hand, oral drug bioavailability is very important, especially the elderly gastrointestinal absorption ability is poorer, therefore directly influence the treatment effect, this also is the important reason for the rule of imported drugs market. But in terms of ease the symptoms of Parkinson's disease, the curative effect of levodopa is difficult to replace, is late onset or have decreased with intelligent important therapy for patients with symptoms. 

 

3, he carpenters, steady growth of sales 

 

Well he carpenters COMT inhibitor is a kind of good security, getting listed on the American FDA approval in 1999. Public hospitals in the key domestic cities against Parkinson's drug market, he was third in carpenters. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital er he carpenters use total amount is 27.68 million yuan, year-on-year growth of 1.47% last year, the steady growth of the overall market. 

 

 

 

4, pyrazole bei er: potential to dig 

 

Pyrazole bei, made by servier, sinopharm tianjin company agent, commodity called tai serta (Trastal). The drug is a kind of ergot class dopaminergic agonist, metabolism, interact with other drugs in the possibility of a few. Main indications, arterial lesions of pain symptoms of Parkinson's disease (walking painful cramp), loop source sex eye disorders, etc. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital pyrazole bei to drug, total amount is 20.58 million yuan, a year-on-year growth of 0.40% a year. 

 

 

 

5, division to gillan: momentum it progresses by leaps and bounds 

 

Company to gillan is a selective - B monoamine oxidase inhibitors, usually for advanced treatment of Parkinson's disease, is also the catalog of national health care drugs income. CFDA has approved shenzhen walter rand pharmaceutical co., nanjing green pharmaceutical production secretary to gillan apis, cisco approval shandong green leaves, anhui baker and mount emei in sichuan province pharmaceutical production of oral preparation, and approval of Orion in Finland (Orion Corporation) department to gillan tablet "mi multipyrazoles" (Eldepryl) in China. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital department gillan to use total amount is 12.92 million yuan, year-on-year growth of 33.20% a year. 

 

 

 

(unit: Beijing jia Lin pharmaceutical co.)